143 results on '"Kovatchev, Boris"'
Search Results
2. Neural-Net Artificial Pancreas: A Randomized Crossover Trial of a First-in-Class Automated Insulin Delivery Algorithm.
3. Artificial Intelligence and Machine Learning for Improving Glycemic Control in Diabetes: Best Practices, Pitfalls, and Opportunities.
4. Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial.
5. Predicting Immunological Risk for Stage 1 and Stage 2 Diabetes Using a 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts, with Classification Enhanced by Machine Learning.
6. Clinically Similar Clusters of Daily Continuous Glucose Monitoring Profiles: Tracking the Progression of Glycemic Control Over Time.
7. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
8. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.
9. Closed-Loop and Artificial Intelligence–Based Decision Support Systems.
10. Essential Continuous Glucose Monitoring Metrics: The Principal Dimensions of Glycemic Control in Diabetes.
11. Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis.
12. Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes.
13. Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes.
14. Decision Support Systems and Closed‐Loop.
15. Decision Support Systems and Closed-Loop.
16. A Data-Driven Approach to Classifying Daily Continuous Glucose Monitoring (CGM) Time Series.
17. Candidate Selection for Hybrid Closed Loop Systems.
18. A Review of Continuous Glucose Monitoring-Based Composite Metrics for Glycemic Control.
19. Decision Support Systems and Closed‐Loop.
20. Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial.
21. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology.
22. Decision Support Systems and Closed-Loop.
23. Creating the Artificial Pancreas: This Wearable Device Senses Blood Glucose and Administers Insulin Accordingly.
24. The Digital/Virtual Diabetes Clinic: The Future Is Now—Recommendations from an International Panel on Diabetes Digital Technologies Introduction.
25. The Digital/Virtual Diabetes Clinic: The Future Is Now-Recommendations from an International Panel on Diabetes Digital Technologies Introduction.
26. Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?
27. The closed‐loop artificial pancreas in 2020.
28. Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes.
29. Randomized Controlled Trial of Mobile Closed-Loop Control.
30. Closed loop control in adolescents and children during winter sports: Use of the Tandem Control‐IQ AP system.
31. Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.
32. Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia.
33. Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes.
34. Use of an Ultrarapid Acting Insulin Analog with Control-IQ: A Case Report.
35. Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus.
36. Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors.
37. Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study.
38. Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D.
39. Individually Adaptive Artificial Pancreas in Subjects with Type 1 Diabetes: A One-Month Proof-of-Concept Trial in Free-Living Conditions.
40. Future of Automated Insulin Delivery Systems.
41. Performance of an Artificial Pancreas System for Young Children with Type 1 Diabetes.
42. In silico assessment of biomedical products: The conundrum of rare but not so rare events in two case studies.
43. Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery.
44. First Look at Control-IQ: A New-Generation Automated Insulin Delivery System.
45. Accuracy of Continuous Glucose Monitoring in Patients After Total Pancreatectomy with Islet Autotransplantation.
46. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.
47. Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report.
48. The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes.
49. Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.
50. Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.